Increased plasma conc w/ medicinal products that inhibit transporter proteins including hepatic uptake transporter OATP1B1 & efflux transporter BCRP. Increased exposure w/ PIs. Increased AUC & C
max in combination of 2 PIs (300 mg atazanavir/100 mg ritonavir), respectively. Increased C
max & AUC w/ gemfibrozil, fenofibrate, other fibrates & ≥1 g/day of niacin. Increased AUC w/ ezetimibe. Decreased plasma conc w/ antacids containing Al- & Mg- hydroxide. Decreased AUC
(0-t) & C
max w/ erythromycin. Increased risk of accumulation w/ ticagrelor. Increased AUC w/ sofosbuvir/velpatasvir/voxilaprevir, ciclosporin, darolutamide, regorafenib, atazanavir/ritonavir, simeprevir, ombitasvir/paritaprevir/ritonavir/dasabuvir, grazoprevir/elbasvir, glecaprevir/pibrentasvir, lopinavir/ritonavir, clopidogrel, gemfibrozil, eltrombopag, darunavir/ritonavir, tipranavir/ritonavir, dronedarone, itraconazole. Decreased AUC w/ baicalin. Increased INR w/ vit K antagonists eg, warfarin, or another coumarin anticoagulant. Increased AUC of OCs eg, ethinyl estradiol & norgestrel. Fusidic acid.